Build status - In Progress

Studying imlifidase in comparison to the standard of care in the management of highly sensitized kidney transplant patients.

Recruiting
18 years - 70 years
All
Phase 3
2 participants needed
1 Location

Brief description of study

The purpose of this study is to demonstrate the efficacy and safety of imlifidase in comparison to the standard of care (SoC) in the management of highly sensitized transplant patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Kidney Transplant
  • Age: 18 years - 70 years
  • Gender: All

  • Patients with Cronic Kidney Disease stage 5, highly sensitized with a cPRA of 99.9% or higher. 

Updated on 04 Aug 2024. Study ID: 850733

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center